Department of Biology, Faculty of Sciences, University of Zabol, Zabol, Iran.
Department of Chemistry, Faculty of Sciences, University of Zabol, Zabol, Iran.
Mol Biol Rep. 2021 Apr;48(4):3827-3840. doi: 10.1007/s11033-021-06363-4. Epub 2021 Apr 25.
Ribosome inactivating proteins (RIPs) as family of anti-cancer drugs recently received much attention due to their interesting anti-cancer mechanism. In spite of small drugs, RIPs use the large-size effect (LSE) to prevent the efflux process governed by drug resistance transporters (DRTs) which prevents inside of the cells against drug transfection. There are many clinical translation obstacles that severely restrict their applications especially their delivery approach to the tumor cells. As the main goal of this review, we will focus on trichosanthin (TCS) and gelonin (Gel) and other types, especially scorpion venom-derived RIPs to clarify that they are struggling with what types of bio-barriers and these challenges could be solved in cancer therapy science. Then, we will try to highlight recent state-of-the-arts in delivery of RIPs for cancer therapy.
核糖体失活蛋白（RIPs）作为一类抗癌药物，由于其有趣的抗癌机制，最近受到了广泛关注。尽管这些药物体积较小，但它们利用大尺寸效应（LSE）来阻止耐药转运体（DRTs）控制的外排过程，从而防止细胞内药物转染。有许多临床转化障碍严重限制了它们的应用，特别是它们递送到肿瘤细胞的方法。作为本次综述的主要目标，我们将重点关注天花粉蛋白（TCS）和相思豆毒素（Gel）以及其他类型的 RIPs，特别是蝎毒液衍生的 RIPs，以阐明它们正在与哪些类型的生物屏障作斗争，以及这些挑战在癌症治疗科学中可以得到解决。然后，我们将尝试强调 RIPs 用于癌症治疗的最新进展。
